Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat plus aromatase inhibitor versus aromatase inhibitor alone after poor response to neoadjuvant chemotherapy in HR-positive/HER2-negative breast cancer
ChiCTR2100042420Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tucidinostat in breast cancer (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoints: Clinical response rate and Modified Preoperative Endocrine Prognostic Index. Started Jan 2021; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100042420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042420.